Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23287889 | 0.80 | LPL (0.44) | LPLLIPGANPEPLAP3 | |
| SCHEMBL32690651 | 0.79 | LPL (0.36) | LPLLIPGSMN1; SMN2MAOAKDM4E | |
| SCHEMBL3930607 | 0.77 | LPL (0.38) | LPLLIPGMAOBMAOASLC6A4 | |
| SCHEMBL24087070 | 0.77 | LPL (0.42) | LPLLIPGMAOBMAOAPTPN1 | |
| SCHEMBL15191536 | 0.77 | PTPN1 (0.41) | MAOBMAOAPTPN1CDK2GSK3B | |
| SCHEMBL2027186 | 0.77 | LPL (0.48) | LPLLIPGCA2ANPEPLAP3 | |
| SCHEMBL23287852 | 0.74 | PIN1 (0.48) | SMN1; SMN2MAOBMAOAPTGS2KDM4E | |
| SCHEMBL23287870 | 0.74 | ALDH1A1 (0.48) | SMN1; SMN2MAOBMAOAPTGS2KDM4E | |
| SCHEMBL5899734 | 0.74 | LPL (0.54) | LPLLIPGCA2ANPEPLAP3 | |
| SCHEMBL15573635 | 0.73 | JAK2 (0.41) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| WO-2025087274-A1 | AZABICYCLO DERIVATIVE AND PREPARATION METHOD THEREFOR, AND USE | 浙江海正药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-23 | — | — | US | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | LPL 3805/4885LIPG 2561/4885SMN1; SMN2 1578/4885 |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LPL 4118/4885LIPG 1619/4885SMN1; SMN2 4213/4885 |
| US-20110152273-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LPL 4118/4885LIPG 1619/4885SMN1; SMN2 4213/4885 |
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | LPL 35/4885LIPG 29/4885SMN1; SMN2 1590/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | LPL 4810/4885LIPG 4621/4885SMN1; SMN2 2401/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | LPL 3217/4885LIPG 4522/4885SMN1; SMN2 3253/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | LPL 3868/4885LIPG 3101/4885SMN1; SMN2 2248/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LPL 4118/4885LIPG 1619/4885SMN1; SMN2 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.